Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
Amgen filed a European application for etelcalcetide, an intravenous drug for kidney dialysis that the company believes can usurp its own Sensipar.
Sage Therapeutics is pressing forward in the field of tremor treatment after its lead drug notched a positive--though not statistically significant--effect on the debilitating condition in Phase II, results the company believes will help light the way for a bigger trial.
Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's shares soaring. But negotiations between the two have since fallen apart, according to Bloomberg.
Shire and Sangamo Biosciences are going their separate ways after three-plus years of collaboration in gene editing, with each company hanging on to the programs best aligned to its goals.
Amgen's investigational bone-growing drug met its main goal in a late-stage trial, clearing its first Phase III hurdle by besting an Eli Lilly blockbuster for osteoporosis.
Sanofi is backing out of a collaboration with Ardelyx that could have paid out nearly $200 million, returning a handful of candidate treatments for high phosphates in patients with kidney disease.
Trevena's treatment for pain following abdominoplasty met its goals in a Phase IIb study, clearing the way for late-stage development and sending the company's share price soaring.
A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.
Alexion Pharmaceuticals is no longer a one-product company, winning tandem European approvals for two rare disease drugs it hopes will mimic the success of Soliris, the world's most expensive treatment.
Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.